Respiratory syncytial virus (RSV) is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop pulmonary disease and/or asthma from RSV that persists throughout adult life making them susceptible to re-infection. Currently, there are no approved vaccines for RSV.
In November 2010, NanoBio received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective nanoemulsion (NE) adjuvanted vaccine for RSV. This grant supported NanoBio’s initial preclinical development program, including studies in mice, cotton rats and non-human primates. These studies demonstrated that both intranasal and intramuscular NE-RSV vaccines induce robust protective immunity, without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail.
Data from NanoBio’s cotton rat and non-human primate studies are pending publication. However, the initial studies in mice conducted by the University of Michigan and NanoBio have been published1. As shown in the charts below, these studies demonstrate robust Th1, Th17 and antibody responses from the intranasal NE-RSV vaccine, as well as protection following challenge.
Immunogenicity in mice: